stock
Sun Pharma’s GLP-1 Breakthrough: Affordable Weight-Loss and Diabetes Care Launches in India
Generic Semaglutide Hits the Market as ‘Noveltreat’ and ‘Sematrinity’ Following Expiry of Global Patent
In a landmark move for Indian healthcare, Sun Pharmaceutical Industries has officially launched its generic versions of the blockbuster drug semaglutide. Following the patent expiry of the innovator molecule (originally marketed by Novo Nordisk as Ozempic and Wegovy) on March 20, 2026, Sun Pharma has introduced two specialized brands designed to make this "miracle drug" accessible to the Indian masses.
The launch is expected to disrupt the metabolic health market, where high costs have previously limited access to advanced GLP-1 therapies.
Related Articles
stock
India-Italy Strategic Pivot: Rajnath Singh to Host Italian Counterpart for High-Level Defence Talks
Meeting Set for April 30 in New Delhi; Focus on "Make in India" Co-Production, Submarine Tech, and Maritime Security
Apr 29, 2026
stock
Adani Power Q4 Earnings: Net Profit Jumps 52% to ₹4,017 Crore
Consolidated Profit Surpasses Estimates as Lower Expenses and New PPAs Offset Flat Operational Revenue
Apr 29, 2026
stock
The Kremlin Anchors OPEC+ After UAE's Historic Exit
Moscow Reaffirms Alliance with Saudi Arabia as UAE Pivots to "Total Independence" Following Middle East Naval Crisis
Apr 29, 2026
stock
UAE Quits OPEC: A Seismic Shift in the Global Oil Order
Impact on India: "Net Positive" in the Long Run, but High Volatility Ahead as Brent Nears $108
Apr 29, 2026
stock
Blinkit’s "4x" Blueprint: Eternal Projects 60%+ Growth through 2029
CEO Albinder Dhindsa Forecasts Quick Commerce Dominance; Net Profit Jumps 346% as Blinkit Hits EBITDA Positivity
Apr 28, 2026